The study objectives are to assess safety, tolerability and gene expression after a single
dose of non-viral CFTR gene therapy (pGM169/GL67A) administered to the nose and lungs of
patients with cystic fibrosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Imperial College London
Collaborators:
Cystic Fibrosis Trust Royal Brompton & Harefield NHS Foundation Trust University of Edinburgh University of Oxford University of Pennsylvania